PT - JOURNAL ARTICLE AU - Rojo, José Manuel Casas AU - Santos, Juan Miguel Antón AU - Núñez-Cortés, Jesús Millán AU - Lumbreras, Carlos AU - Rincón, José Manuel Ramos AU - Roy-Vallejo, Emilia AU - Artero, Arturo AU - Fernández, Francisco Arnalich AU - Bruñén, Jose Miguel García AU - Núñez, Juan Antonio Vargas AU - Castro, Santiago J. Freire AU - Manzano, Luis AU - Fraile, Isabel Perales AU - Vieitez, Anxela Crestelo AU - Puchades, Francesc AU - Rodilla, Enrique AU - Marquínez, Marta Nataya Solís AU - Tur, David Bonet AU - del Pilar Fidalgo Moreno, María AU - Aizpuru, Eva M Fonseca AU - Sánchez, Francisco Javier Carrasco AU - Pejenaute, Elisa Rabadán AU - Rubio-Rivas, Manuel AU - Peña, José David Torres AU - Huelgas, Ricardo Gómez AU - for the SEMI-COVID-19 Network TI - Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Network AID - 10.1101/2020.05.24.20111971 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.24.20111971 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111971.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111971.full AB - Background Spain has been one of the countries most affected by the COVID-19 pandemic.Objective To create a registry of patients with COVID-19 hospitalized in Spain in order to improve our knowledge of the clinical, diagnostic, therapeutic, and prognostic aspects of this disease.Methods A multicentre retrospective cohort study, including consecutive patients hospitalized with confirmed COVID-19 throughout Spain. Epidemiological and clinical data, additional tests at admission and at seven days, treatments administered, and progress at 30 days of hospitalization were collected from electronic medical records.Results Up to April 30th 2020, 6,424 patients from 109 hospitals were included. Their median age was 69.1 years (range: 18-102 years) and 56.9% were male. Prevalences of hypertension, dyslipidemia, and diabetes mellitus were 50.2%, 39.7%, and 18.7%, respectively. The most frequent symptoms were fever (86.2%) and cough (76.5%). High values of ferritin (72.4%), lactate dehydrogenase (70.2%), and D-dimer (61.5%), as well as lymphopenia (52.6%), were frequent. The most used antiviral drugs were hydroxychloroquine (85.7%) and lopinavir/ritonavir (62.4%). 31.5% developed respiratory distress. Overall mortality rate was 21.1%, with a marked increase with age (50-59 years: 4.2%, 60-69 years: 9.1%, 70-79 years: 21.4%, 80-89 years: 42.5%, ≥ 90 years: 51.1%).Conclusions The SEMI-COVID-19 Network provides data on the clinical characteristics of patients with COVID-19 hospitalized in Spain. Patients with COVID-19 hospitalized in Spain are mostly severe cases, as one in three patients developed respiratory distress and one in five patients died. These findings confirm a close relationship between advanced age and mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In accordance with applicable regulations, the Spanish Agency of Medicines and Medical Products (AEMPS, for its initials in Spanish) has ruled that due to its nature, the study only required the approval of the Ethics Committee and not the Autonomous Community, as in other studies. The SEMI-COVID-19 Registry has been approved by the Provincial Research Ethics Committee of Malaga (Spain).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA